Explore our
PERFECT packaging
selection process.
LEARN
MORE
06/04/2024 13:18:51
Home | Lula’s progress plan for Brazil: A year on
Editor's letter
Contents
Mimotopes Company Insight
Mimotopes
Xylem
Briefing
News in Numbers
Latest News
Latest Deals
Project Updates
Trends & Insight
phasetwo
Datwyler Company Insight
Datwyler
In Depth
Lula’s progress plan for Brazil: A year on
How sham patents are hurting the pharma industry
Tracking the opioid lawsuit settlements amidst calls for oversight
Cell and gene therapy landscape in the US
Q&A: Cell and gene therapy value assessments need a rework to allow access
Pharmaceutical discovery through a gravitational lens
Thematic Take: ESG
Thematic Take: contents
Foreword: A growing sense of urgency in ESG
ESG 1.0 is over – get ready for ESG 2.0
ESG becomes mandatory: how to prepare
Theme timeline: the past, present and future of ESG
Net-zero strategies for the pharma sector
Leading pharma companies and initiatives in the race for net zero
GlobalData’s Christopher Papadopoullos on net-zero strategy for businesses
38% of companies lack an ESG strategy – GlobalData survey
Sustainability challenges in rare disease trials remain, but change is happening
ESCMID 2024: The infectious consequences of climate change
Bring your own device: How patients own tech is being used in clinical trials
Can pharma overcome generative AI’s bias problem?
China-US tensions are spilling into the biotech sector
Japanese patients among least empowered in the developed world
World Air Quality Report: what are the health impacts and where is it worst?
Why has New Zealand U-turned on the world’s first smoking ban?
Microplastics in placentas: how serious is the problem?
Deal activity related to ESG in the pharma industry since 2021
GlobalData Thematic Intelligence
Sponsored Supplements
BEA Technologies
Cytiva
Listings
Events
Innovation Rankings
Buyer's Guides
Next issue
05/22/2024 00:00:00
